Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Broad Clinical Benefit for Seroquel XR (Quetiapine Fumarate Extended Release) With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy

NCT01128114 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01128114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01128114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Broad Clinical Benefit for Seroquel XR (Quetiapine Fumarate Extended Release) With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Terminated
Start date
June 30, 2010
Completion date
March 31, 2011
Enrollment
32 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute bipolar mania